Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo (for etanercept)Drug: Placebo (for sarilumab)
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 776
- Registration Number
- NCT01764997
- Locations
- 🇺🇸
Investigational Site Number 840203, Washington, D.C., District of Columbia, United States
🇦🇷Investigational Site Number 032009, Zarate, Argentina
🇨🇱Investigational Site Number 152018, Santiago, Chile
A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2012-12-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT01755390
- Locations
- 🇪🇸
Sanofi, Barcelona, Spain
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Granulocyte-colony stimulating factor (G-CSF)
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 23
- Registration Number
- NCT01753453
- Locations
- 🇧🇪
Investigational Site Number 056002, Brugge, Belgium
🇱🇹Investigational Site Number 440001, Vilnius, Lithuania
🇪🇪Investigational Site Number 233001, Tallinn, Estonia
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
- Conditions
- Malignant Solid Tumor - Malignant Nervous System Neoplasm
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 39
- Registration Number
- NCT01751308
- Locations
- 🇺🇸
Investigational Site Number 840005, Orlando, Florida, United States
🇺🇸Investigational Site Number 840014, Palo Alto, California, United States
🇨🇦Investigational Site Number 124001, Toronto, Canada
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT01749969
- Locations
- 🇺🇸
Investigational Site Number 840004, San Francisco, California, United States
🇺🇸Investigational Site Number 840003, Columbus, Ohio, United States
🇺🇸Investigational Site Number 840001, Tampa, Florida, United States
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
- Conditions
- Stargardt's Disease
- Interventions
- Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 27
- Registration Number
- NCT01736592
- Locations
- 🇫🇷
Investigational Site Number : 250001, Paris, France
🇺🇸Oregon Health and Science University Site Number : 840001, Portland, Oregon, United States
Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 12
- Registration Number
- NCT01724788
- Locations
- 🇨🇦
Investigational Site Number 124002, Montreal, Canada
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 79
- Registration Number
- NCT01723735
- Locations
- 🇫🇷
Investigational Site Number 250001, Rennes, France
🇫🇷Investigational Site Number 250002, Rueil Malmaison, France
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 63
- Registration Number
- NCT01718353
- Locations
- 🇺🇸
Investigational Site Number 840017, Rockville, Maryland, United States
🇺🇸Investigational Site Number 840003, Birmingham, Alabama, United States
🇺🇸Investigational Site Number 840002, Baltimore, Maryland, United States
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 546
- Registration Number
- NCT01709578
- Locations
- 🇺🇸
Investigational Site Number 840018, Idaho Falls, Idaho, United States
🇺🇸Investigational Site Number 840058, Columbia, South Carolina, United States
🇺🇸Investigational Site Number 840124, Clarksburg, West Virginia, United States